entity

SLC16A7

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about SLC16A7: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

4Connections
0Hypotheses
1Analyses
3Outgoing
1Incoming
0Experiments
1Debates

No AI portrait yet

Outgoing (3)

TargetRelationTypeStr
h-b2ebc9b2targeted_byhypothesis1.00
ENERGY METABOLISMinvolved_inentity0.85
lactate_shuttlingmodulatespathway0.70

Incoming (1)

SourceRelationTypeStr
h-b2ebc9b2targetshypothesis1.00

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
No targeting hypotheses

Mentioning Analyses (1)

Scientific analyses that reference this entity

Why do systemic anti-inflammatory drugs fail in AD despite cardiovascular effica

clinical neurology | 2026-04-08 | 0 hypotheses

Experiments (0)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
No papers found

Debates (1)

Multi-agent debates referencing this entity

The debate noted clinical failures of TNF-α and IL-6 inhibitors in AD despite th

closed · Rounds: 4 · Score: 0.79 · 2026-04-09

Related Research

Hypotheses and analyses mentioning SLC16A7 in their description or question text

No additional research found